New oral agents for type 2 diabetes.
Krentz
Andrew J
AJ
Southampton University Hospitals. a.j.krentz@soton.ac.uk
D020909:Acarbose / Q000494:pharmacology; D002219:Carbamates / Q000494:pharmacology; D002839:Chromans / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D000077205:Pioglitazone; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D000077285:Rimonabant; D045162:Thiazolidinediones / Q000494:pharmacology; D000077288:Troglitazone
D002219:Carbamates; D002839:Chromans; D007004:Hypoglycemic Agents; D010880:Piperidines; D011720:Pyrazoles; D045162:Thiazolidinediones; C072379:repaglinide; D000077288:Troglitazone; D000077285:Rimonabant; D020909:Acarbose; D000077205:Pioglitazone